Navigation Links
Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data

Landmark Study Shows Increased Survival for Non-Small Cell Lung Cancer

WASHINGTON, June 2 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) hailed the release of promising data from the pivotal Phase III First Line in Lung Cancer with Erbitux(R) (FLEX) Study. The data, presented at the American Society of Clinical Oncology (ASCO), showed a significant increase in overall survival in the first line treatment of patients with non-small cell lung cancer (NSCLC).

"This is very exciting news," said Laurie Fenton Ambrose, LCA President & CEO. "The FLEX data shows significant improvements in overall survival for a broad base of patients with no new safety concerns. This is so important to the lung cancer community because it will provide patients and doctors with another treatment option to consider when managing their diagnosis."

The FLEX study, conducted by Merck KGaA, enrolled more than 1,100 patients with Stage IIIb or IV NSCLC who had not previously received chemotherapy. The study included patients of all ages, regardless of their performance status (general well-being) who were diagnosed with all types of NSCLC. Erbitux(R) is a monoclonal antibody designed to inhibit the function of the epidermal growth factor receptor (EGFR). The major side effect from the drug is a rash.

Lung cancer is the leading cancer killer of both men and women in the United States with more than 162,000 deaths expected to occur in 2008, accounting for almost 30% of all cancer deaths.

"This is an important development," said David H. Johnson, MD, Deputy Director, Vanderbilt Ingram Cancer Center. "All lung cancer is notoriously difficult to treat. These results will further our understanding of NSCLC and provide a new standard of care for the lung cancer community."

For more information on the data please visit .

Lung Cancer Alliance ( ) is the only national non-profit organization dedicated solely to patient support and advocacy for those living with or at risk for lung cancer. LCA is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Media Contact:

Kay Cofrancesco


SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:11/25/2015)... Endo International plc (NASDAQ: ENDP ) (TSX: ... and CEO, will discuss corporate updates at the 27 th ... York on Wednesday, December 2, 2015 at 1 ... Relations, and then the link to the event. Participants should ... to visit the site and download any streaming media software ...
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... November 25, 2015 - Will ... Education (CME) --> - Will ... Medical Education (CME) --> - ... Continuing Medical Education (CME) Elsevier ... and services, will feature latest diagnostic imaging textbooks and decision support ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a global ... attracts volunteers together who want to combine talents and resources to help create ... the process. The non-profit launched its first major fundraiser on November 6, 2015 ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, ... Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil ... for the opening of the 5th African Network for Drugs and Diagnostics Innovation, ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to MAP ... the two groups began in 2014 with Vitalalert pledging a portion of every purchase ... in 1954 and is an international Christian-based health organization whose mission is to “advance ...
Breaking Medicine News(10 mins):